For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Sanofi Patient Connection™ Provider Portal

Sanofi Patient Connection™ (SPC) Provider Portal allows you to enroll and manage your patients in the SPC suite of patient access services. The secure web-based portal is available 24 hours a day, 7 days a week.

Using the SPC Provider Portal you can:

Determine a patient’s
prescription insurance
benefits and options.

Find out if a patient
is eligible to receive
prescription medication
at no cost.

Learn about additional resources
and support available to patients
such as transportation assistance,
nutritional supplements and
support groups.

If you are new to the SPC Provider Portal, simply visit to register.

Tap into support for JEVTANA today

SPC Provider Portal

We look forward to talking to you and providing support to your eligible patients.

Call 1.888.VISITSPC (1.888.847.4877)

Monday through Friday, 9am-8pm ET
or go to available 24/7 and
enroll your patients today.



  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave

You are leaving to view another Sanofi Genzyme Corporation website.